Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Y-90 Radioembolization for Colorectal Liver Metastases
NCT05195710Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2022
- Primary completion
- Mar 2028
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yttrium-90 resin microspheres in colorectal liver metastases (CRLM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Feasibility of Y-90 TARE directed to the right hemi-liver at 1 year and Safety of Y-90 TARE directed to the right hemi-liver at 1 year. Started Nov 2022; status: recruiting.
02
Drugs
yttrium-90 resin microspheres
03
Conditions
colorectal liver metastases (CRLM)
Beyond the preview
Go deeper on NCT05195710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195710.